To explore the effect of combined therapy of sevelamer carbonate with cinacalcet on hyperphosphatemia and blood pressure variation in maintenance hemodialysis (MHD) patients.

A retrospective study was conducted to analyze the clinical data of 82 patients with MHD complicated with hyperphosphatemia admitted to our hospital from January 2022 to December 2023. According to the treatment method, they were divided into a single group and a combination group, with 41 patients in each group. The single group was treated with sevelamer carbonate, while the combination group was treated with sevelamer carbonate plus cinacalcet. Both groups were treated for 3 months. Calcium and phosphorus metabolism indexes, blood pressure variation, renal function, and microinflammation status of the patients before and after treatment were compared, and the occurrence of adverse reactions was also compared between the two groups.

After the 3 months treatment, serum calcium levels of the two groups increased, and the serum calcium level of the combination group was also higher than that of the single group (all P<0.05). The levels of blood phosphorus, intact parathyroid hormone, systolic blood pressure variability, diastolic blood pressure variability, blood urea nitrogen, serum creatinine, β2-microglobulin, high-sensitivity C-reactive protein, tumor necrosis factor-α, and interleukin-6 in both groups decreased after the treatment, and the above indexes were also lower in the combination group than in the single group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

The combined therapy of sevelamer carbonate with cinacalcet could increase blood calcium, reduce blood phosphorus and intact parathyroid hormone, and improve blood pressure variability in the MHD patients complicated with hyperphosphatemia.